EicOsis Newsletter
April 2026

Download the Newsletter to a PDF here: EicOsis Newsletter – April 2026

Dear EicOsis Community,

This quarter’s update is especially meaningful for everyone at EicOsis.

At the beginning of the year, we lost Dr. Bruce Hammock, an extraordinary scientist, mentor, and the founder and Chair of EicOsis. Bruce’s work reshaped how the scientific community understands inflammation and pain, and his vision is the reason this company exists. Just as importantly, his integrity, curiosity, and rigor shaped the culture we continue to carry forward.

Bruce would jokingly remind us that “If science is not fun, it shouldn’t be done.” Although seemingly lighthearted, he would say this as motivation to persevere through tough experiments. I think about this often, and as we share our ‘fun’ updates with you in our newsletters, I hope to one day translate these results to improve the lives of patients in desperate need of better treatments for their disease.

While his passing is deeply personal for many of us, it has also sharpened our sense of purpose. Bruce believed that great science carries responsibility, the responsibility to translate insight into real therapies for people who need them the most. That conviction is guiding our work every day.

Over the past quarter, EicOsis has continued to advance its lead program with focus and momentum, while refining our clinical strategy to accelerate development timelines and expand impact. In this issue, we are also sharing planned new indications designed to streamline regulatory pathways and shorten time to market, an approach that reflects Bruce’s lifelong commitment to translational science.

This newsletter is dedicated to Bruce’s legacy, not as a look back, but as a reaffirmation. Our mission is clear, our science is strong, and our commitment to execution has only grown stronger. We are grateful to our collaborators, investors, and broader community for your continued trust and support as we move forward, carrying Bruce’s vision into the next chapter of EicOsis.

Cindy McReynolds

CEO, EicOsis

IN THIS NEWSLETTER

Industry Analysis
Financial Summary
Potential Indications
Clinical Update
Upcoming Milestones
What’s Next…

Dr. Bruce Hammock picture in a laboratory

Industry Analysis

Market Landscape: Selective Capital, Strong Science

Life sciences financing remains active and disciplined, with investors deploying capital selectively toward programs that demonstrate clear translational logic and defined development milestones. Recent data shows that early-stage rounds continue to drive company formation, while the majority of capital is concentrated from Series A through later stages, where scientific validation, regulatory clarity, and execution readiness justify larger commitments.

Importantly, while AI-enabled approaches remain part of the ecosystem, most funded activity continues to favor biology- and chemistry-led innovation, reinforcing a market that prioritizes substance over narrative. Taken together, the current environment is not risk-off, but gated, rewarding capital efficiency and programs positioned to advance decisively toward patients.

The major difference from the first half of 2025 is that the funds are spreading more evenly across deals, rather than the very small earlier rounds and very big later rounds we saw in the first half of the year.

Financial Summary

Financial Position and Outlook

EicOsis continues to operate from a position of financial discipline and stability. Throughout 2025, we maintained a conservative expense policy across our non-dilutive funding portfolio, including grants from Department of Defense, National Institutes of Health, and Michael J. Fox Foundation. This approach has allowed us to advance our programs responsibly while preserving flexibility as our development plans evolve.

We closed 2025 in solid financial shape and entered 2026 with a budget designed to support targeted proof of concept studies that will enable a meaningful step forward in our clinical and regulatory strategy. These investments are focused, intentional, and aligned with accelerating the overall trajectory of our lead program.

In parallel, we are approaching a significant investment milestone that we look forward to sharing in a future update. As we prepare for the conclusion of this funding round, we anticipate selectively expanding our team with several pivotal roles to support the next phase of execution.

We remain focused on prudent capital deployment, operational rigor, and building a foundation that supports long-term value creation. More to come, and we look forward to sharing further progress in the next issue.

Representation of EicOsis assets

Potential Indications

The incidence of both neurodegenerative diseases and chronic inflammatory conditions are on the rise, in part due to an ageing population. In fact, neurodegenerative disorders, such as Parkinson’s Disease or Alzheimer’s Disease, are now the leading cause of disability in the world. For most of these conditions, there is a pressing unmet need for novel therapies that can alter disease progression.

Neuroinflammation is a key process in the pathogenesis of neurodegenerative disorders, but has often been overlooked as a potential therapeutic target. Inhibition of the soluble epoxide hydrolase (sEH) with EicOsis drug candidates plays a crucial role in neuroinflammation and neurodegenerative diseases by reducing harmful inflammatory mediators in the brain. In fact, inhibition of sEH has consistently shown neuroprotective effects in various animal models, including Alzheimer’s disease, Parkinson’s disease, ischemia-induced brain injury and traumatic brain injury. Inhibiting sEH in these serious neurologic disorders does not only reduce neuroinflammation and other associated pathologic changes; it also has shown to reduce cognitive impairment and have beneficial behavioral effects in these models. EicOsis is advancing its drug candidates for the treatment of neurodegenerative disorders, including Parkinson’s Disease and Alzheimer’s Disease.

In addition, we have continued making exciting progress in clinical development for pain. In fact, a new clinical trial just opened recruitment for patients suffering neuropathic pain from a traumatic spinal cord injury in Augusta, Georgia. We are also designing new clinical trials targeting populations where pain control has been elusive, specifically those with chronic kidney disease that cannot take any of the common available therapies for pain. Explore our promising pipeline and make sure to subscribe to our newsletter to stay informed on the latest breakthroughs, updates, and partnership opportunities!

Clinical Update

EicOsis continues to advance the clinical development of EC5026, our once-daily oral soluble epoxide hydrolase (sEH) inhibitor, across multiple therapeutic areas.

In Parkinson’s disease, a second participant has successfully completed dosing in our Michael J. Fox Foundation for Parkinson’s Research-funded clinical trial being conducted at UC Davis Medical Center. This study represents an important step in evaluating EC5026’s potential role in modulating neuroinflammation in neurodegenerative diseases.

In the area of pain, our clinical trial evaluating EC5026 for neuropathic pain due to traumatic and degenerative spinal cord injury is currently open for enrollment in Augusta, Georgia. We are also preparing to initiate clinical evaluation of EC5026 in patients with osteoarthritis who have chronic kidney disease (CKD), a population with significant unmet medical needs. Many of these patients are unable to take commonly prescribed analgesics due to renal safety concerns, yet uncontrolled osteoarthritis pain limits mobility and exercise, which are critical to maintaining kidney health. Through a collaboration with Dr. Baback Roshanravan, Professor of Medicine and nephrologist at UC Davis, we are planning to start a new clinical trial to characterize the safety profile of EC5026 in patients with CKD, helping lay the foundation for therapeutic options in this particularly vulnerable population.

Upcoming Milestones

EicOsis continues to make meaningful progress across our clinical and development programs as we advance our portfolio of soluble epoxide hydrolase (sEH) inhibitors toward patients with significant unmet medical needs.

Parkinson’s Disease Study

Dosing has been successfully completed for two subjects in our Parkinson’s Disease study. Additional participants are currently being enrolled as we continue to assess safety and pharmacologic activity in this important neuroinflammatory indication.

Osteoarthritis / Chronic Kidney Disease (OA/CKD) Study

As we work to address the substantial unmet need for safe and effective pain therapies in osteoarthritis—particularly in patients with comorbid chronic kidney disease—we expect to begin enrollment outreach in Q2. This study builds upon our strong preclinical data supporting the potential benefit of sEH inhibitors in osteoarthritis.

Manufacturing and Supply Expansion

Our second manufacturing run is on track for completion by Q2. This production campaign will provide the clinical-grade material required to support our ongoing and planned studies, ensuring we are well positioned to advance multiple programs in parallel.

What’s Next…

The progress outlined in this update reflects our commitment to moving forward with focus, discipline, and purpose. From early clinical execution to the expansion of our development pipeline and team, EicOsis continues to translate years of foundational work into meaningful forward momentum.

The initiation of patient dosing across multiple programs marks an important inflection point for us. At the same time, the steps we are taking to strengthen our organization and advance key enabling studies underscore our commitment to building a development engine that is both rigorous and scalable. The decision to advance additional indications into the clinic this year is equally intentional, grounded in strong pre-clinical data and a clear assessment of where we can create impact most efficiently.

All of this progress is inseparable from the scientific vision that Bruce Hammock instilled in EicOsis. Bruce believed deeply in translational science that serves patients, and in the responsibility to pursue that mission with integrity and urgency. As we move forward, that ethos continues to guide how we set priorities, make investments, and measure success. In that spirit, we are also in the process of organizing the first Bruce Hammock Symposium, which will bring together members of the scientific and clinical community to honor his legacy and further the work he cared about so deeply.

We are grateful for the continued support of our collaborators, investors, and broader community. The road ahead is ambitious, but our direction is clear, our science is strong, and our resolve has never been greater. We look forward to sharing continued progress in the months ahead.

Cindy McReynolds
CEO, EicOsis

Bruce with Hulahalla, the first ‘patient’ dosed. She is still alive today!